Investigating pathways involved in liver disease related to alcohol use
Official title: Targeting PI3K/BRD4 and Hedgehog Pathway in Alcohol Associated Liver Disease
Funded at University of Toledo Health Sci Campus · NIH-11135983 · Data updated 2026-11-12
This study is looking at how specific cellular pathways related to alcohol use can cause liver damage and inflammation, with the goal of finding new treatments that could help people with alcohol-related liver disease feel better.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo Health Sci Campus NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project start | July 11, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $105,638 |
| NIH project number | 5K01AA029763-05 |
| Project ID | NIH-11135983 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with alcohol-associated liver disease or those experiencing liver complications due to alcohol use.
✕Less likely to help
Patients with liver disease not related to alcohol consumption may not benefit from this research.
What this research studies
This research focuses on understanding how certain cellular pathways, specifically the PI3K/BRD4 and Hedgehog pathways, contribute to liver disease caused by alcohol consumption. The study aims to explore how these pathways interact and lead to inflammation and liver damage. By targeting these pathways, the research seeks to develop new therapeutic strategies that could improve outcomes for individuals suffering from alcohol-associated liver disease. Patients may benefit from advancements in treatment options that arise from this investigation.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve liver health for patients with alcohol-related liver disease.
How similar studies have gone: Previous research has shown promise in targeting similar pathways for liver diseases, indicating potential for success in this approach.
Where this research is happening
-
University of Toledo Health Sci Campus
Toledo, United States Active
Researchers
- Principal investigator: Kumar, Virender — University of Toledo Health Sci Campus
- Study coordinator: Kumar, Virender
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.